Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Nov;151(2):202-207. doi: 10.1016/j.ygyno.2018.08.006. Epub 2018 Aug 31.

PMID:
30174176
2.

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH.

Gynecol Oncol. 2011 Sep;122(3):495-500. doi: 10.1016/j.ygyno.2011.05.040.

3.

A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.

Park H, Parker GL, Boardman CH, Morris MM, Smith TJ.

Support Care Cancer. 2011 Jun;19(6):859-63. doi: 10.1007/s00520-011-1099-7. Epub 2011 Jan 27.

4.

Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.

Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH.

Gynecol Oncol. 2010 Dec;119(3):531-7. doi: 10.1016/j.ygyno.2010.08.020. Epub 2010 Sep 15.

5.

Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ.

Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Review. No abstract available.

PMID:
19763437
6.

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D.

J Clin Oncol. 2009 Oct 1;27(28):4649-55. doi: 10.1200/JCO.2009.21.8909. Epub 2009 Aug 31.

7.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH.

J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30.

8.

Biologic therapeutics and molecular profiling to optimize wound healing.

Menke MN, Menke NB, Boardman CH, Diegelmann RF.

Gynecol Oncol. 2008 Nov;111(2 Suppl):S87-91. doi: 10.1016/j.ygyno.2008.07.052. Epub 2008 Oct 1. Review.

9.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

10.

Peritoneal carcinomatosis from cervical cancer detected by F-18 FDG positron emission tomography.

Spottswood SE, Lopatina OA, Fey GL, Boardman CH.

Clin Nucl Med. 2005 Jan;30(1):56-9. No abstract available.

PMID:
15604978
11.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

12.

Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.

Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ.

Am J Obstet Gynecol. 2002 Jun;186(6):1167-73.

PMID:
12066092
13.

EGF/ErbB receptor family in ovarian cancer.

Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC.

Cancer Treat Res. 2002;107:247-58. Review.

PMID:
11775453
14.

A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.

Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1175-85.

15.

Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.

Quillin JM, Boardman CH, Bodurtha J, Smith T.

Gynecol Oncol. 2001 Oct;83(1):168-70. No abstract available.

PMID:
11585435
16.

Surgery in ovarian cancer.

Boardman CH, Webb MJ.

Eur J Gynaecol Oncol. 2001;22(2):89-95. Review.

PMID:
11446487
17.
18.

Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer.

Boardman CH, Webb MJ, Jefferies JA.

Gynecol Oncol. 2000 Oct;79(1):120-3.

PMID:
11006043
19.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

20.

A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.

Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ.

J Immunol Methods. 1998 Oct 1;219(1-2):23-43.

PMID:
9831386
21.

Airbag deployment following a motor vehicle accident in pregnancy.

Sims CJ, Boardman CH, Fuller SJ.

Obstet Gynecol. 1996 Oct;88(4 Pt 2):726. No abstract available.

PMID:
8841272

Supplemental Content

Loading ...
Support Center